UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 7, 2011

 

 

VIROPHARMA INCORPORATED

(Exact Name of Registrant as Specified in its Charter)

 

 

 

DELAWARE   0-021699   23-2789550

(State or Other Jurisdiction of

Incorporation or Organization)

 

(Commission

File Number)

  (I.R.S. Employer
Identification Number)
397 STOCKTON DRIVE, EXTON, PENNSYLVANIA   19341
(Address of Principal Executive Offices)   (Zip Code)

(610) 458-7300

(Registrant’s Telephone Number, Including Area Code)

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

 

 


Item 8.01 Other Events.

On November 7, 2011, DuoCort Pharma AB (“DuoCort”) announced that DuoCort’s orphan drug Plenadren was granted European marketing authorization for adrenal insufficiency. On October 26, 2011, ViroPharma Incorporated (the “Company”) signed a definitive agreement to acquire DuoCort (the “Transaction”). European marketing authorization for DuoCort’s orphan drug Plenadren is a condition to closing the Transaction. Subject to satisfaction of closing conditions, the Company and DuoCort expect to complete the acquisition in November 2011.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    VIROPHARMA INCORPORATED
Date: November 7, 2011     By:  

/s/ J. Peter Wolf

     

J. Peter Wolf

Vice President, General Counsel and Secretary